参术益中汤联合mFOLFOX6方案治疗低位直肠癌疗效评价

Efficacy of Shenzhuyizhong Decoction Combined with mFOLFOX6 Chemotherapy Regimen in the Treatment of Patients with Low Rectal Cancer

目的探讨参术益中汤联合m FOLFOX6方案治疗低位直肠癌术后的效果及安全性。方法选取医院2016年3月至2019年3月收治的低位直肠癌患者86例,按盲法随机分为观察组和对照组,各43例。两组患者均给予m FOLFOX6方案治疗,观察组患者联合参术益中汤治疗。结果治疗后,观察组患者的客观缓解率、疾病控制率分别为69.77%和83.72%,明显高于对照组的48.84%和62.79%(P<0.05);观察组患者的血清肿瘤标志物癌胚抗原、糖链抗原19-9、糖链抗原50水平均低于对照组(P<0.05),观察组患者的CD3+和CD4+细胞阳性率与CD4+/CD8+均高于对照组,但CD8+细胞阳性率低于对照组(P<0.05);观察组无进展生存期、总体生存期均长于对照组(P<0.05);两组患者不良反应发生率相当(20.93%比13.95%,P>0.05)。结论参术益中汤联合m FOLFOX6方案治疗低位直肠癌的近期疗效显著,可降低肿瘤标志物水平,提高患者的免疫功能,一定程度上延长生存期,且安全性良好。

Objective To investigate the efficacy and safety of Shenshuyizhong Decoction combined with m FOLFOX6 chemotherapy regimen in the treatment of patients with low rectal cancer.Methods Totally 86 patients with low rectal cancer admitted to our hospital from March 2016 to March 2019 were selected and randomly divided into the observation group and the control group,43 cases in each group.The patients in the two groups were treated with m FOLFOX6 chemotherapy regimen,on this basis,the patients in the observation group were treated with Shenzhuyizhong Decoction.Results After treatment,the objective remission rate(ORR)and disease control rate(DCR)in the observation group were 69.77%and 83.72%,respectively,which were significantly higher than 48.84%and62.79%in the control group(P<0.05).The levels of serum carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)and carbohydrate antigen 50(CA50)in the observation group were lower than those in the control group(P<0.05).The positive rates of CD3+,CD4+cells and the CD4+/CD8+in the observation group were higher than those in the control group,while the positive rate of CD8+cells was lower than that in the control group(P<0.05).The progression-free survival(PFS)and overall survival(OS)in the observation group were longer than those in the control group(P<0.05).The incidence of adverse reactions in the two groups was similar(20.93%vs.13.95%,P>0.05).Conclusion Shenzhuyizhong Decoction combined with m FOLFOX6 chemotherapy regimen has significant short-term effect on patients with low rectal cancer.It can reduce the level of tumor markers,improve the immune function of patients,prolong the survival period of patients to a certain extent,and have good safety.